OSE Immunotherapeutics
OSE.PAOSE Immunotherapeutics is an integrated biotechnology company focused on controlling the immune system for therapeutic benefit in cancer and inflammatory diseases. The company's strategy is built on three proprietary research platforms that generate novel candidates in immuno-oncology and immuno-inflammation. Its most advanced program, Tedopi®, has received positive recommendations from an independent data monitoring committee in its pivotal Phase 3 ARTEMIA trial. OSE aims to accelerate development through strategic partnerships with premier international pharmaceutical, clinical, and academic collaborators.
OSE.PA · Stock Price
Historical price data
AI Company Overview
OSE Immunotherapeutics is an integrated biotechnology company focused on controlling the immune system for therapeutic benefit in cancer and inflammatory diseases. The company's strategy is built on three proprietary research platforms that generate novel candidates in immuno-oncology and immuno-inflammation. Its most advanced program, Tedopi®, has received positive recommendations from an independent data monitoring committee in its pivotal Phase 3 ARTEMIA trial. OSE aims to accelerate development through strategic partnerships with premier international pharmaceutical, clinical, and academic collaborators.
Technology Platform
Three proprietary platforms: 1) T-cell activation via neo-epitopes for cancer vaccines, 2) Reprogramming suppressive cells in the tumor microenvironment, and 3) Modulating T-effector and regulatory T-cells for immune tolerance in inflammatory diseases.
Pipeline
10| Drug | Indication | Stage | Watch |
|---|---|---|---|
| OSE2101 + Docetaxel | Patients With Non-Small Cell Lung Cancer | Phase 3 | |
| OSE2101 + Docetaxel + Pemetrexed | Non Small Cell Lung Cancer | Phase 3 | |
| OSE-127 + Placebo | Ulcerative Colitis | Phase 2 | |
| FOLFIRI + OSE2101 | Pancreatic Ductal Adenocarcinoma | Phase 2 | |
| FR104 | Kidney Transplantation | Phase 1/2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
In NSCLC, Tedopi® competes with other late-line therapies including chemotherapy, targeted agents, and other immunotherapies. Its differentiation is as an off-the-shelf, multi-neoepitope vaccine. In immuno-inflammation, it would face entrenched biologics from large pharma; its novel T-cell modulation approach aims to offer a differentiated mechanism of action.